Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-03-26
2002-12-17
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06495584
ABSTRACT:
This application is a national stage filing of PCT International Application No. PCT/F199/00793, filed on Sep. 27, 1999, which published in the English language.
BACKGROUND OF THE INVENTION
The present invention relates to a new method of administering 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof. Accordingly, the present invention relates to an intraspinal administration of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof to obtain analgesia. The intraspinal administration is intented to include epidural, intrathecal and intrarrhachidian administration. Accordingly, the present invention relates to a method for obtaining analgesia in a mammal by administering 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof intraspinally. Particularly, the present invention relates to an intraspinal administration of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof for obtaining analgesia without sedation. Further, the present invention relates to a method of using 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof as an adjunct to anaesthesia by administering the drug intraspinally. The present invention also relates to a method for treating a mammal by administering 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof intraspinally. Further, the present invention relates to the use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt in the manufacture of a medicament for intraspinal administration.
3-(1H-Imidazol-4-ylmethyl)-indan-5-ol has the following formula:
3-(1H-Imidazol-4-ylmethyl)-indan-5-ol is described in WO 97/12874 as an &agr;
2
-receptor agonist useful in the treatment of hypertension, glaucoma, migraine, diarrhea, ischemia, addiction to chemical substances, anxiety, especially preoperative anxiety, and different neurological, musculosketal, psychiatric and cognition disorders as well as a sedative and an analgesic agent, nasal decongestant, and as an adjunct to anaesthesia. Enteral, topical, and parenteral routes of administration and a method for producing the compound are discussed in WO 97/12874.
Opioids, especially morphine, are routinely used for intraspinal and epidural administration to give analgesia. However, according to Eisenach J. E. (Exp. Opin. Invest. Drugs 3(10), 1994, 1005-1010) the major concern limiting the use of intraspinal morphine is the 0.1 to 0.2% incidence of severe respiratory depression, occurring six to twelve hours after injection.
&agr;
2
-Receptor agonists are being evaluated for obtaining analgesia by administering them intrathecally or epidurally. At the moment, the only &agr;
2
-receptor agonist approved by the FDA for obtaining analgesia by epidural administration is clonidine (DURACLONO®). According to Laitin S. & Wallac M. (“&agr;
2
-agonists for analgesia”, Emerging Drugs 1996, Chapter Eighteen, 377-399, Ashley Publications Ltd.) the lipid solubility of clonidine results in significant systemic absorption when administered epidurally. This results in significant systemic side-effects, such as, sedation and hypotension. It is suggested that agents with lower lipid solubility may be advantageous. Also, Eisenach J. C. in Exp. Opin. Invest. Drugs 3(10), 1994, 1005-1010, states that injectable &agr;
2
-agonist drug development would logically focus on compounds of low lipophilicity. Increasing lipophilicity is associated with more rapid and extensive absorption into the vasculature and redistribution in the body, which for &agr;
2
-agonists could lead to a greater likelihood or intensity of sedative and haemodynamic side-effects.
Further, Staats P. S. & Mitchell V. D. (Progr. Anesthesiol. 11(19), 1997, 367-382) state that, although clonidine has been demonstrated to be a powerful analgesic agent, the clinical use of intrathecal clonidine has been limited by side-effects, primarily hypotension and bradycardia.
SUMMARY OF THE INVENTION
Applicants have discovered that 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof is an ideal agent to be administered to a mammal intraspinally for obtaining analgesia. Accordingly, an object of the invention is to provide a method for obtaining analgesia by administering 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof to a mammal intraspinally in an amount sufficient to give the desired therapeutic effect. Applicants surprisingly discovered that 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof can be administered intraspinally to a mammal obtaining analgesia without side-effects, such as sedation. This is surprising because 3-(1H-imidazol-4-ylmethyl)-indan-5-ol has a considerable higher lipophilicity when compared to clonidine at physiological pH. Because of the higher lipophilicity it would have been expected that 3-(1H-imidazol-4-ylmethyl)-indan-5-ol would cause also the systemic adverse effects when administered intraspinally as clonidine does.
It should be noted that the method for obtaining analgesia in a mammal encompasses all of the potential conditions that require the treatment of pain, e.g., intraoperative pain; postoperative pain; obstetric pain; chronic pain, such as cancer-related pain and neuropathic pain; and spastic paraplegia. Further, it should be noted that intraspinal administration is intented to include epidural, intrathecal (i.e., within the spinal subarachnoid or subdural space), and intrarrhachidian administration.
An object of the invention is also to provide a method for treating a mammal by administering 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharnmaceutically acceptable ester or salt thereof intraspinally for a time sufficient to give the therapeutic effect.
An aspect of the invention is also to provide a method of using 3-(1H-imidazol-4--ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof intraspinally as an adjunct to anaesthesia.
A further aspect of the invention relates to a use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof in the manufacture of a medicament for intraspinal administration.
In a further aspect, the invention relates to a use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof in an intraspinal administration to a mammal to obtain analgesia.
Additional objects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The objects and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
REFERENCES:
patent: 5801188 (1998-09-01), Hassenbusch, III et al.
patent: 6313311 (2001-11-01), Karjalainen et al.
patent: 0 424 059 (1991-04-01), None
patent: WO 97/12874 (1997-04-01), None
Peter Staats et al., “Future Directions for Intrathecal Therapies”, Progress in Anesthesiology, pp. 367-382.
Laitin et al., “&agr;2-agonists for analgesia”, Emerging Drugs, vol. 18, pp. 377-389 (1996).
James Eisenach, “Alpha-2 agonists and analgesia”, Exp. Opin. Invest. Drugs, vol. 3 (10), pp. 1005-1010 (1994).
Tony Yasksh et al., “Chronic Catheterization of the Spinal Subarachnoid Space”, Physiology & Behavior, vol. 17, pp. 1031-1036 (1976).
Co-pending U.S. patent application No. 10/018,545, § 371 filing date of Mar.
Haapalinna Antti
Lehtimäki Jyrki
Leino Tiina
Viitamaa Timo
Virtanen Raimo
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Hui San-ming
Orion Corporation
Travers Russell
LandOfFree
Use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2953964